Literature DB >> 15900683

Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon.

Kyle A Garver1, Scott E LaPatra, Gael Kurath.   

Abstract

The level of protective immunity was determined for Chinook Oncorhynchus tshawytscha and sockeye/kokanee salmon (anadromous and landlocked) O. nerka following intramuscular vaccination with a DNA vaccine against the aquatic rhabdovirus, infectious hematopoietic necrosis virus (IHNV). A DNA vaccine containing the glycoprotein gene of IHNV protected Chinook and sockeye/kokanee salmon against waterborne or injection challenge with IHNV, and relative percent survival (RPS) values of 23 to 86% were obtained under a variety of lethal challenge conditions. Although this is significant protection, it is less than RPS values obtained in previous studies with rainbow trout (O. mykiss). In addition to the variability in the severity of the challenge and inherent host susceptibility differences, it appears that use of a cross-genogroup challenge virus strain may lead to reduced efficacy of the DNA vaccine. Neutralizing antibody titers were detected in both Chinook and sockeye that had been vaccinated with 1.0 and 0.1 pg doses of the DNA vaccine, and vaccinated fish responded to viral challenges with higher antibody titers than mock-vaccinated control fish.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900683     DOI: 10.3354/dao064013

Source DB:  PubMed          Journal:  Dis Aquat Organ        ISSN: 0177-5103            Impact factor:   1.802


  34 in total

1.  Analysis of DNA-vaccinated fish reveals viral antigen in muscle, kidney and thymus, and transient histopathologic changes.

Authors:  Kyle A Garver; Carla M Conway; Diane G Elliott; Gael Kurath
Journal:  Mar Biotechnol (NY)       Date:  2005-07-22       Impact factor: 3.619

2.  Introduction of translation stop codons into the viral glycoprotein gene in a fish DNA vaccine eliminates induction of protective immunity.

Authors:  Kyle A Garver; Carla M Conway; Gael Kurath
Journal:  Mar Biotechnol (NY)       Date:  2006-06-12       Impact factor: 3.619

3.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 4.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

Review 5.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 6.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

7.  CCL17 combined with CCL19 as a nasal adjuvant enhances the immunogenicity of an anti-caries DNA vaccine in rodents.

Authors:  Yan-Hong Yan; Fei Yu; Chang Zeng; Li-Hua Cao; Zhou Zhang; Qing-An Xu
Journal:  Acta Pharmacol Sin       Date:  2016-08-15       Impact factor: 6.150

8.  Modulating APOBEC expression enhances DNA vaccine immunogenicity.

Authors:  Rafael Ribeiro Almeida; Rui André Saraiva Raposo; Fernanda Caroline Coirada; Jamile Ramos da Silva; Luís Carlos de Souza Ferreira; Jorge Kalil; Douglas F Nixon; Edecio Cunha-Neto
Journal:  Immunol Cell Biol       Date:  2015-05-08       Impact factor: 5.126

Review 9.  Microneedles: an innovative platform for gene delivery.

Authors:  Joanne McCaffrey; Ryan F Donnelly; Helen O McCarthy
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 5.671

10.  Immune Efficacy of a Genetically Engineered Vaccine against Lymphocystis Disease Virus: Analysis of Different Immunization Strategies.

Authors:  Fengrong Zheng; Xiuqin Sun; Xing'an Wu; Hongzhan Liu; Jiye Li; Suqi Wu; Jinxing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2011-07-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.